–  Increases quarterly cash dividend 15% to $0.15 per share LEXINGTON, Ky., Feb. 20, 2025 /PRNewswire/ -- Somnigroup International Inc. (NYSE:SGI, ", Company", or ", Somnigroup", )) today announced that its Board of Directors has declared a first quarter cash dividend on its common stock of $0.15 per share. The dividend is payable on March 20, 2025 to shareholders of record as of March 6, 2025.  Somnigroup Chairman and CEO Scott Thompson commented, "We are pleased to announce this increase to our quarterly dividend. Our Board of Directors increased the quarterly dividend to $0.15 per share based on the strength of the Company's market position and demonstrated ability to generate significan

- Fourth Quarter 2024 Net Sales increased 3% to $1.2 Billion- Strong Fourth Quarter Operating Income Growth - Fourth Quarter 2024 EPS of $0.40 and Adjusted EPS(1) of $0.60, increased 13%- Increased Quarterly Cash Dividend 15% to $0.15 per share- Issues 2025 Guidance and Perspective on Consolidated Long-Term Growth LEXINGTON, Ky., Feb. 20, 2025 /PRNewswire/ -- As previously announced, Tempur Sealy International, Inc. changed its name to Somnigroup International Inc. (NYSE:SGI, ", Company", )) effective February 18, 2025. The Company today announced financial results for the fourth quarter and year ended December 31, 2024. The Company also issued financial guidance for the full year 2025, whi

Today Hasbro, a leading games, IP, and toy company, is unveiling a new strategic plan, ‘Playing to Win', taking the company through 2027. At the heart of Playing to Win is Hasbro's mission to create joy and community through the magic of play. Through play-fueled engagement and partner-scaled co-investment, Hasbro will seek to expand its reach from over 500 million kids, families, and fans today to over 750 million by 2027. Through 2027, we expect an average of mid-single digit revenue growth and 50-100 basis points of annual operating profit margin improvement. By 2026 Hasbro's gross debt to adjusted EBITDA ratio is projected to stand at 2.5x. And by 2027 Hasbro's operational excellence pr

– Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Received FDA approval of GOMEKLI™ (mirdametinib) for the treatment of adult and pediatric patients with symptomatic NF1-PN not amendable to complete resection – – Ended 2024 with $461.9 million in cash, cash equivalents and marketable securities – STAMFORD, Conn., Feb. 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the fourth quarter and full year periods ended December 31, 2024 and provi

Citigroup upgraded Light & Wonder from Neutral to Buy

Redburn Atlantic initiated coverage of HubSpot with a rating of Buy

Redburn Atlantic initiated coverage of Adobe with a rating of Neutral

Redburn Atlantic initiated coverage of Workday with a rating of Neutral

4 - US ENERGY CORP (0000101594) (Issuer)

4 - American Strategic Investment Co. (0001595527) (Issuer)

4 - Rezolute, Inc. (0001509261) (Issuer)

4/A - Vislink Technologies, Inc. (0001565228) (Issuer)

4 - US ENERGY CORP (0000101594) (Issuer)

4 - Extra Space Storage Inc. (0001289490) (Issuer)

4 - Fold Holdings, Inc. (0001889123) (Issuer)

4 - Fold Holdings, Inc. (0001889123) (Issuer)

8-K - HASBRO, INC. (0000046080) (Filer)

8-K - Primo Brands Corp (0002042694) (Filer)

8-K - SOMNIGROUP INTERNATIONAL INC. (0001206264) (Filer)

8-K - LKQ CORP (0001065696) (Filer)

For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con

For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this

Company Granted Request to Continue its Listing on NasdaqAppoints Thorain Ko to Lead Business Development Initiatives BANGKOK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to specific conditions. Additionally, the Company announced the appointment of Mr. Thorain Ko as Business Development Director to drive its expansion initiatives. Nasdaq Listing UpdateThe Pane

NEW YORK, Feb. 19, 2025 /PRNewswire/ -- SanDisk Corp. (NASD: SNDK) will replace Leslie Inc. (NASD: LESL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, February 25. S&P 500 constituent Western Digital Corp. (NASD: WDC) is spinning off SanDisk in a transaction expected to be completed on February 24. Western Digital will remain in the S&P 500 post spin-off. Leslie's market capitalization is no longer representative of the small cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Feb 25, 2025 S&P SmallCap 600 Additi

The Board of Directors of Asbury Automotive Group, Inc. (NYSE:ABG) ("Asbury" or the "Company"), one of the largest automotive retail and service companies in the U.S., today announced that Senior Vice President of Operations Daniel E. Clara has been promoted to Chief Operating Officer effective February 17, 2025. Mr. Clara has over 23 years of extensive automotive retail experience. Prior to his 5 years as SVP of Operations, he held positions as regional vice president, market director, general manager, other store-level department leadership roles, and store-level frontline retail positions at Asbury. "Dan has done a great job leading store operations for Asbury for the past 5 years," sai

Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif., Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring continued execution momentum and commitment to driving long-term stockholder value. The Company also confirmed that Deep Track Capital ("Deep Track") has submitted a letter purporting to nominate four candidates to stand for election to the Dynavax Board of Directors at the Company's 2025 Annual Meeting of Stockholders.

–  Increases quarterly cash dividend 15% to $0.15 per share LEXINGTON, Ky., Feb. 20, 2025 /PRNewswire/ -- Somnigroup International Inc. (NYSE:SGI, ", Company", or ", Somnigroup", )) today announced that its Board of Directors has declared a first quarter cash dividend on its common stock of $0.15 per share. The dividend is payable on March 20, 2025 to shareholders of record as of March 6, 2025.  Somnigroup Chairman and CEO Scott Thompson commented, "We are pleased to announce this increase to our quarterly dividend. Our Board of Directors increased the quarterly dividend to $0.15 per share based on the strength of the Company's market position and demonstrated ability to generate significan

- Fourth Quarter 2024 Net Sales increased 3% to $1.2 Billion- Strong Fourth Quarter Operating Income Growth - Fourth Quarter 2024 EPS of $0.40 and Adjusted EPS(1) of $0.60, increased 13%- Increased Quarterly Cash Dividend 15% to $0.15 per share- Issues 2025 Guidance and Perspective on Consolidated Long-Term Growth LEXINGTON, Ky., Feb. 20, 2025 /PRNewswire/ -- As previously announced, Tempur Sealy International, Inc. changed its name to Somnigroup International Inc. (NYSE:SGI, ", Company", )) effective February 18, 2025. The Company today announced financial results for the fourth quarter and year ended December 31, 2024. The Company also issued financial guidance for the full year 2025, whi

– Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Received FDA approval of GOMEKLI™ (mirdametinib) for the treatment of adult and pediatric patients with symptomatic NF1-PN not amendable to complete resection – – Ended 2024 with $461.9 million in cash, cash equivalents and marketable securities – STAMFORD, Conn., Feb. 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the fourth quarter and full year periods ended December 31, 2024 and provi

ATLANTA, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that the company will release its fourth quarter and full year results before the market open on Thursday, March 13, 2025, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13750192. The replay will be available until March

SC 13D/A - CVR ENERGY INC (0001376139) (Subject)

SC 13D/A - INCOME OPPORTUNITY REALTY INVESTORS INC /TX/ (0000949961) (Subject)

SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

SC 13D - Neuronetics, Inc. (0001227636) (Subject)

Recently, on July 4, 2024, a significant insider purchase was recorded at Allied Gaming & Entertainment Inc. as Large owner Choi Roy bought $456,750 worth of shares (360,000 units at $1.27), increasing direct ownership by 14% to 2,871,822 units (SEC Form 4). This purchase is notable for the size of the transaction and the percentage increase in direct ownership, indicating a strong belief in the company's future prospects. Insider purchases are generally viewed positively by investors as they signal confidence from those with intimate knowledge of the company's operations. Examining other recent insider transactions at Allied Gaming & Entertainment Inc., we notice a few patterns worth explo

Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto

Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan